HighLife Announces Breakthrough CE Mark Approval for TMVR
HighLife has secured CE Mark approval for its transfemoral Transcatheter Mitral Valve Replacement system, enabling initial commercial availability across...
NMD Pharma Announces Phase 2a Results for Ignaseclant in CMT
NMD Pharma reported topline Phase 2a results for ignaseclant in Charcot‑Marie‑Tooth disease (CMT) showing the study did not meet...
Ascendis Pharma to Report FY 2025 Financial Results Feb. 11
Ascendis Pharma will report full-year 2025 financials and deliver a business update on February 11, 2026, after U.S. market...
Adaptive Bio Reports Q4 and Full Year 2025 Financials
Adaptive Biotechnologies reported a breakout 2025: total revenue rose 55% to $277 million, driven by 46% growth in its...
Announcing Ocular Therapeutix’s New NASDAQ Inducement Grant
Ocular Therapeutix has granted inducement equity awards to five newly hired non-executive employees, including options to purchase 13,850 shares...
XORTX Announces Successful Acquisition of Renal Technology
XORTX Therapeutics has extended the deadline to close its acquisition of Vectus Biosystems’ renal anti‑fibrotic program, including the novel...
Syndax Announces Participation at Guggenheim Biotech Summit
Syndax Pharmaceuticals will spotlight its strategy at the 2026 Guggenheim Emerging Outlook: Biotech Summit on February 12, with a...
Rhythm Announces Participation in Guggenheim Biotech Summit
Rhythm Pharmaceuticals will put its finance chief on stage next week. The company’s CFO is scheduled for a fireside...
INVO Fertility Outlines Surging Growth, Strengthened Outlook
INVO Fertility has outlined its strongest operating stance to date, pointing to clinic-level profitability across three sites, a pending...
Novartis Delivered Strong Sales Growth and 40% Core Margin
Novartis closed 2025 with net sales of $54.5 billion, up 8% in constant currencies, core operating income up 14%,...